Insider Trading March 16, 2026

Nutex Health Legal Chief Adds to Stake After Sharp Share Drop

Chief Legal Officer Pamela Montgomery purchases $7,020 of common stock as the company copes with a steep quarterly revenue decline

By Maya Rios NUTX
Nutex Health Legal Chief Adds to Stake After Sharp Share Drop
NUTX

Pamela W. Montgomery, Nutex Health Inc.'s Chief Legal Officer-Healthcare, bought 79 shares of the company's common stock on March 13, 2026, spending $7,020 at $88.87 per share. The purchase follows a near 10% slide over the prior week and comes amid a 41.1% year-over-year drop in Nutex Health's fourth-quarter 2025 revenue. Montgomery also reported a separate restricted stock units transaction on March 10, 2026. After the transactions she directly holds 2,758 shares and 4,441 Restricted Stock Units. Independent analysis cited in reports indicates the shares are trading below Fair Value.

Key Points

  • Pamela W. Montgomery purchased 79 shares of Nutex Health common stock on March 13, 2026, paying $88.87 per share for a total of $7,020.
  • Montgomery also reported a March 10, 2026 transaction involving 1,523 Restricted Stock Units and now directly holds 2,758 shares and 4,441 RSUs.
  • Nutex Health reported a 41.1% year-over-year drop in revenue for Q4 2025; the stock had been down nearly 10% over the prior week and was trading about 49% below its 52-week high - sectors affected include healthcare and equity markets.

Pamela W. Montgomery, who serves as Chief Legal Officer-Healthcare at Nutex Health Inc. (NASDAQ:NUTX), executed an open-market purchase of company common stock on March 13, 2026. Montgomery acquired 79 shares at $88.87 per share, for a total consideration of $7,020.

The trade occurred against a backdrop of recent weakness in the stock - shares had fallen nearly 10% over the prior week and were trading roughly 49% below their 52-week high of $193.07 at the time of the purchase.

Separately, Montgomery reported another transaction on March 10, 2026, involving 1,523 Restricted Stock Units (RSUs). Combining these filings, Montgomery now holds 2,758 shares of Nutex Health common stock directly and 4,441 Restricted Stock Units.

Valuation note: An InvestingPro analysis referenced in reports states the stock appears undervalued at the then-current price, with shares trading below Fair Value. That analysis is tied to a Pro Research Report available for this and more than 1,400 other US-listed equities.

Company performance: Nutex Health disclosed a pronounced revenue decline for the fourth quarter of 2025, with total revenue down 41.1% compared with the same period a year earlier. The quarterly shortfall has generated investor concern despite commentary that the company produced an overall strong full-year performance.

The sharp quarterly revenue contraction and the recent share-price weakness have prompted closer attention from analysts and market participants, who are monitoring Nutex Health's financial trajectory and any strategic responses management may pursue. The company’s ability to restore revenue momentum was highlighted as a focus for stakeholders following the release.

Montgomery's purchase adds insider buying to the list of recent developments. While the investment increases her direct stake modestly, the transactions also coincide with the firm's challenged quarter and a valuation assessment that indicates shares were trading below Fair Value at the reported levels.

No additional details regarding future insider transactions, management plans or operational changes were disclosed in the filings reporting these trades.

Risks

  • Significant quarterly revenue decline - Nutex Health’s Q4 2025 total revenue fell 41.1% year-over-year, creating uncertainty about near-term financial performance (impacts healthcare and investor confidence).
  • Recent share-price weakness - shares were down nearly 10% over the prior week and trading approximately 49% below the 52-week high, which may reflect market concerns and elevate trading volatility (impacts equity markets and investors).
  • Limited disclosure on strategic response - filings did not provide details on management actions to address the revenue decline, leaving questions about the company’s plans and timeline for recovery (impacts stakeholders assessing operational and financial strategy).

More from Insider Trading

Vornado Director Acquires $766,500 in Stock as Company Posts Mixed Q4 Results Mar 16, 2026 American Industrial Partners Disposes $173.6M of V2X Stock in March Filing Mar 16, 2026 Federated Hermes VP Sells $1.71 Million in Class B Shares; Company Posts Strong Q4 2025 Results Mar 16, 2026 Akamai EVP Joseph Paul C completes $531,256 stock sale under 10b5-1 plan Mar 16, 2026 Absci Chief Innovation Officer Buys $229,000 of Stock Amid Clinical Setback and Strategic Shift Mar 16, 2026